PDL BioPharma Inc

PDL BioPharma — UBS Global Healthcare Conference 2018

30 slides from PDL BioPharma's conference presentation, May 22, 2018

  1. Slide 1: UBS Global Healthcare Conference

    Slide 1: UBS Global Healthcare Conference

    PDL UBS Global Healthcare Conference May 22, 2018 PDL BioPharma, Inc. Nasdaq: PDLI

  2. Slide 2: Forward-Looking Statements

    Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation contains forward-looking statements including PDL's expectations with respect to its future royalty revenues, expenses, net income and cash provided by operating activities. Each of these forward-looking statements involves risks and uncertainties. Actual

  3. Slide 3: PDL's Evolving Strategic Focus

    Slide 3: PDL's Evolving Strategic Focus

    PDL’s Evolving Strategic Focus Mission: Maximizing shareholder value primarily through the acquisition and management of a portfolio of healthcare companies. Building a portfolio of operating companies: + Noden Pharma DAC, a specialty pharma company domiciled in Ireland. — 100% owned by PDL. - Tektu

  4. Slide 4: Investment Highlights

    Slide 4: Investment Highlights

    Investment Highlights * Compelling opportunity for Tekturna © /Rasilez © in the global hypertension market as alternatives to ACE inhibitors and ARBs. — Acquired the brands from Novartis in July 2016. - Growth strategy to build upon recently stabilized Rx trends. + LENSAR is the femtosecond laser te

  5. Slide 5: Experienced Leadership

    Slide 5: Experienced Leadership

    Experienced Leadership Executive Management Board of Directors John McLaughlin— CEO Paul Edick Dominique Monnet- President David Gryska Jody Lindell Peter Garcia - CFO Christopher Stone - General Counsel Jill Jene, Ph.D. — Vice President, Business Development John McLaughlin Samuel Saks, M.D. Paul S

  6. Slide 6: Noden Pharma

    Slide 6: Noden Pharma

    PDL NODEN y PHARMA

  7. Slide 7: Novartis/Noden/Tekturna Deal

    Slide 7: Novartis/Noden/Tekturna Deal

    Novartis/Noden/Tekturna® Deal * Noden and Tekturna ® were PDL’s first operational acquisitions under its new growth strategy. * Total Tekturna®/Rasilez® potential purchase price: Up to $294 million. — $110 million paid at closing in July 2016. — $89 million paid at first anniversary in July 2017. —

  8. Slide 8: Current Noden Products

    Slide 8: Current Noden Products

    Current Noden Products * Tekturna® (U.S.), Rasilez® (ex-U.S.) — contain aliskiren, a direct renin inhibitor for hypertension that reduces plasma renin by inhibiting conversion of angiotensinogen to angiotensin I. — Not for use with ACE inhibitors or ARBs in patients with diabetes or renal impairment

  9. Slide 9: The Tekturna Opportunity

    Slide 9: The Tekturna Opportunity

    The Tekturna® Opportunity Hypertension is a chronic condition with serious long-term health implications that affects about 29% of adults in the U.S.1. ACEls (angiotensin converting enzyme inhibitors) and ARBs (angiotensin receptor blockers) are typically first- and second- line therapies. Tekturna

  10. Slide 10: Executing Well Targeted Promotion

    Slide 10: Executing Well Targeted Promotion

    10 Executing Well Targeted Promotion ACE/ ARB Intolerant: SWITCH CCB Notat Goal: ADD Estimated 6 million patients Estimated 3.3 million patients

  11. Slide 11: Tekturna Enjoys Strong Access

    Slide 11: Tekturna Enjoys Strong Access

    " Tekturna® Enjoys Strong Access Source of Tekturna® Business 42% 53% Jan-18 = Commercial m Medicare = All Other = Cash = All Medicaid Tekturna® Plan Coverage Commercial Medicare D = Preferred = Preferred (PA/ST) = Covered = Covered (PAST) = Not Covered Source: IQVIA PlanTrak & Managed Markets Insig

  12. Slide 12: Stabilization of Tekturna Prescriptions

    Slide 12: Stabilization of Tekturna Prescriptions

    Stabilization of Tekturna® Prescriptions Tekturna® Prescription Data - All Strengths — U.S. Z Noden resumes Noden promotion Field with 40 Force reps increased to 60 reps

  13. Slide 13: Maximize Rasilez Profitability Ex-U.S.

    Slide 13: Maximize Rasilez Profitability Ex-U.S.

    Maximize Rasilez® Profitability Ex-U.S. Headquartered in Ireland, Noden DAC built a full cross-functional team and a comprehensive distributor network ex-U.S. Starting November 1, 2017 Noden DAC assumed commercialization for Rasilez ® and Rasilez HCT ® in Switzerland and the EU, focusing on countrie

  14. Slide 14: Tekturna/Rasilez Intellectual Property

    Slide 14: Tekturna/Rasilez Intellectual Property

    Tekturna®/Rasilez® Intellectual Property + United States — Composition-of-matter protection to 2018 for Tekturna®; listed in the Orange Book; — Plus 6-month extension from successful completion of pediatric testing requirements. — Composition-of-matter protection until 2022 for Tekturna® HCT. — Form

  15. Slide 15: Experienced Noden Pharma Team

    Slide 15: Experienced Noden Pharma Team

    15 Experienced Noden Pharma Team Chief Executive Officer, Alan Markey + Previously Managing Director of Baxter Healthcare Limited (Ireland), Assistant VP for Enbrel - EU. Head of Sales and Marketing U.S., Michael McCann + Previously head of U.S. Cardiovascular at Sanofi Genzyme, VP of Global Strateg

  16. Slide 16: Criteria for Building a Portfolio of Operating Companies

    Slide 16: Criteria for Building a Portfolio of Operating Companies

    16 Criteria for Building a Portfolio of Operating Companies * Focus on commercial-stage products or companies whose performance may be improved through access to PDL’s capital and expertise. ¢ Primary targets are biopharma products or companies that either present synergies with the existing Noden P

  17. Slide 17: Cataract Laser with Augmented Reality

    Slide 17: Cataract Laser with Augmented Reality

    PDL CATARACT LASER WITH AUGMENTED REALTY

  18. Slide 18: LENSAR

    Slide 18: LENSAR

    18 | LENSAR + Converted to equity from debt transaction + Leading global developer and manufacturer of femtosecond cataract lasers (FLS) for the growing cataract surgery market. + Cataract surgery is the highest-volume surgical procedure globally. — Market penetration of FLS ~7% of total proceduresi

  19. Slide 19: LENSAR Highlights

    Slide 19: LENSAR Highlights

    19 LENSAR Highlights Leading Technology Platform Positioned for Growth Cataract surgery is the highest volume surgical procedure performed worldwide with over 26.2 million surgeries estimated to be performed in 2017 Integration of preoperative diagnostics into the cataract refractive suite is drivin

  20. Slide 20: Overview of Royalty and Debt Portfolio

    Slide 20: Overview of Royalty and Debt Portfolio

    PDL Overview of Royalty and Debt Portfolio

  21. Slide 21: Royalty & Debt Investments to Date

    Slide 21: Royalty & Debt Investments to Date

    16 Royalty & Debt Investments to Date Royalty Transaction ‘Senior Secured Financing Wellstat Diagnostics, LUC we $44,000,000 November2012 Royalty Acquisition HK Depomed 240,500,000 October 2013, Financing AR | LENSAR $60,000,000 October 2013, ‘Senior Secured inancing Oo DURATA THERAPEUTICS $70,000,0

  22. Slide 22: Strong Cash Flow to Fund Business

    Slide 22: Strong Cash Flow to Fund Business

    Strong Cash Flow to Fund Business Glumetza 3€Devomed” YYVALEANT indefinite Pees. 6/2018 Dent Loe, 5/2026 - $240.5M $325.4M ~ yanssen Jr 9/2023 Bente! oy, 12/2026 J — Payoff $100.0M $120.0M3 peinaleeaies Ed sanoricenzvey 4/2022 $65.6M $9.2M ZALVISO” AcelRx | sate | 1/2032 $65.0M $0.2M or 3X investmen

  23. Slide 23: Financials

    Slide 23: Financials

    PDL Financials

  24. Slide 24: Share Repurchase Programs

    Slide 24: Share Repurchase Programs

    Share Repurchase Programs ¢ Previous Program - $30 Million - In March 2017 PDL’s board authorized the repurchase of PDL common stock having an aggregate value of up to $30 million through March 2018. - Total repurchased under this program over 4 months was approximately 13.3 million shares at an ave

  25. Slide 25: First Quarter 2018 Income Statement

    Slide 25: First Quarter 2018 Income Statement

    First Quarter 2018 Income Statement Three Months Ended March 31, (in thousands, except per share amounts) 2018 2017 Royalties from Queen et al. patents $2,783 _§ 14,156 Royalty rights - change in fair value 41,091 13,146 Interest revenue 749 5,457 Product revenue, net 23,324 12,581 License and other

  26. Slide 26: Strong Balance Sheet

    Slide 26: Strong Balance Sheet

    Strong Balance Sheet ($ in millions) Cash, cash equivalents and short-term investments $405 Total Assets $1,100 Debt: 2.75% Convertible Debt - due 12/2021 ($3.81 conversion p/s)' $150 1) PDLentered into a capped call transaction to offset potential dilution subject to a cap of $4.88. PDL

  27. Slide 27: Goal: Fill Gap Between Book Value and Stock Price

    Slide 27: Goal: Fill Gap Between Book Value and Stock Price

    Goal: Fill Gap Between Book Value and Stock Price PDL’s book value per share increased to $5.60 in the period ending March 31, 2018 PDL's Book Value Per Share, ) oO SPRPENNNNUWUW ERENT D REASRSASRSASRSASRSasRSas 5 2 8 S$ 3 S&S &3 28 82 8 82 8 8 8 5 8 FS 8 $8 s § & 8 & § @ & & § & B & § BES § & ¢ 3 $

  28. Slide 28: Value of Balance Sheet Assets

    Slide 28: Value of Balance Sheet Assets

    Value of Balance Sheet Assets Assets 1200 Balance 3/31/2018 1000 Selected Component $ millions Per Share 800 Royalty Rights $ 3417 $ 227 Noden & LensarBook Value $ 213.2 $ 1.42 600 Notes Receivable $70.7 $ 0.47 [SEN Total Investments $ 625.6 $ 4.16 400 mm Cash $405.1 $ 2.69 200 Debt $ (150.0) $ (1.0

  29. Slide 29: Key Information and Figures

    Slide 29: Key Information and Figures

    Key Information and Figures NASDAQ Ticker PDLI HQ Location Incline Village, Nevada Share Price $2.70 as of 05/16/2018 Book Value as of 12/31/2017 $5.60 per share Current Deployed on Royalty Investments $396 million Current Deployed on Debt Investments $20 million Current Deployed on Equity Investmen

  30. Slide 30: Investment Highlights and Priorities

    Slide 30: Investment Highlights and Priorities

    Investment Highlights and Priorities HIGHLIGHTS Tekturna ® and Rasile: re important products for treating hypertension with a differentiated MOA and potential upside in revenues if promoted appropriately. Noden investment was immediately cash flow accretive to PDL Ateam with demonstrated ability to

Source: SEC EDGAR · 8-K filed May 22, 2018

More decks from PDL BioPharma Inc